Unlike standard federal certifications that merely oversee general laboratory operations, New York’s Clinical Laboratory Evaluation Program (CLEP) requires a rigorous, test-level validation of the actual methodology. The Wadsworth Center, which administers the program, evaluates the scientific validity of each specific assay, a hurdle that most U.S. states do not impose. Legacy’s tests, which utilize computer-assisted sperm analysis (CASA) technology, are now recognized as meeting or exceeding the federal CLIA requirements.

For patients across New York, the approval confirms that at-home sample collection can provide clinical-grade results comparable to traditional, in-person diagnostic settings. Dr. Scott Lundy, Legacy's Chief Medical Officer, noted that this certification underscores the clinical validity of their platform, while CEO Khaled Kteily emphasized the achievement as a major step in expanding access to high-quality fertility care. While the approval validates the laboratory testing process itself, it does not extend to the specific collection devices or AI-driven software used during development.